BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chow MYT, Qiu Y, Lam JKW. Inhaled RNA Therapy: From Promise to Reality. Trends Pharmacol Sci 2020;41:715-29. [PMID: 32893004 DOI: 10.1016/j.tips.2020.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Qin M, Du G, Sun X. Recent Advances in the Noninvasive Delivery of mRNA. Acc Chem Res 2021;54:4262-71. [PMID: 34756014 DOI: 10.1021/acs.accounts.1c00493] [Reference Citation Analysis]
2 Sasso JM, Ambrose BJB, Tenchov R, Datta RS, Basel MT, DeLong RK, Zhou QA. The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments. J Med Chem 2022. [PMID: 35533054 DOI: 10.1021/acs.jmedchem.2c00024] [Reference Citation Analysis]
3 Xu Y, Thakur A, Zhang Y, Foged C. Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects. Pharmaceutics 2021;13:177. [PMID: 33525500 DOI: 10.3390/pharmaceutics13020177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Matuszak M, Ochowiak M, Włodarczak S, Krupińska A, Doligalski M. State-of-the-Art Review of The Application and Development of Various Methods of Aerosol Therapy. Int J Pharm 2021;:121432. [PMID: 34971755 DOI: 10.1016/j.ijpharm.2021.121432] [Reference Citation Analysis]
5 Yeo WS, Ng QX. Passive inhaled mRNA vaccination for SARS-Cov-2. Med Hypotheses 2021;146:110417. [PMID: 33277107 DOI: 10.1016/j.mehy.2020.110417] [Reference Citation Analysis]
6 Steinle H, Weber J, Stoppelkamp S, Große-Berkenbusch K, Golombek S, Weber M, Canak-Ipek T, Trenz SM, Schlensak C, Avci-Adali M. Delivery of synthetic mRNAs for tissue regeneration. Adv Drug Deliv Rev 2021;179:114007. [PMID: 34710530 DOI: 10.1016/j.addr.2021.114007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhang D, Tian J, Wang Y, Lu J. Evitar: designing anti-viral RNA therapies against future RNA viruses. Bioinformatics 2022:btac144. [PMID: 35294970 DOI: 10.1093/bioinformatics/btac144] [Reference Citation Analysis]
8 Munir M, Jena L, Kett V, Dunne N, Mccarthy H. Spray drying: Inhalable powders for pulmonary gene therapy. Materials Science and Engineering: C 2021. [DOI: 10.1016/j.msec.2021.112601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shepard KB, Vodak DT, Kuehl PJ, Revelli D, Zhou Y, Pluntze AM, Adam MS, Oddo JC, Switala L, Cape JL, Baumann JM, Banks M. Local Treatment of Non-small Cell Lung Cancer with a Spray-Dried Bevacizumab Formulation. AAPS PharmSciTech 2021;22:230. [PMID: 34467438 DOI: 10.1208/s12249-021-02095-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kumbhar P, Manjappa A, Shah R, Jha NK, Singh SK, Dua K, Disouza J, Patravale V. Inhalation delivery of repurposed drugs for lung cancer: Approaches, benefits and challenges. J Control Release 2021;341:1-15. [PMID: 34780880 DOI: 10.1016/j.jconrel.2021.11.015] [Reference Citation Analysis]
11 Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet 2022:S0168-9525(22)00018-X. [PMID: 35303998 DOI: 10.1016/j.tig.2022.02.006] [Reference Citation Analysis]
12 Hussain Y, Cui JH, Khan H, Makvandi P, Alam W. Biomacromolecule-mediated pulmonary delivery of siRNA and anti-sense oligos: challenges and possible solutions. Expert Rev Mol Med 2021;23:e22. [PMID: 34906269 DOI: 10.1017/erm.2021.25] [Reference Citation Analysis]
13 Wu R, Luo KQ. Developing effective siRNAs to reduce the expression of key viral genes of COVID-19. Int J Biol Sci 2021;17:1521-9. [PMID: 33907515 DOI: 10.7150/ijbs.59151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mohammed Y, Holmes A, Kwok PCL, Kumeria T, Namjoshi S, Imran M, Matteucci L, Ali M, Tai W, Benson HAE, Roberts MS. Advances and future perspectives in epithelial drug delivery. Adv Drug Deliv Rev 2022;186:114293. [PMID: 35483435 DOI: 10.1016/j.addr.2022.114293] [Reference Citation Analysis]
15 Artzy-Schnirman A, Arber Raviv S, Doppelt Flikshtain O, Shklover J, Korin N, Gross A, Mizrahi B, Schroeder A, Sznitman J. Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics. Adv Drug Deliv Rev 2021;176:113901. [PMID: 34331989 DOI: 10.1016/j.addr.2021.113901] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
16 de Brito e Cunha D, Frederico ABT, Azamor T, Melgaço JG, da Costa Neves PC, Bom APDA, Tilli TM, Missailidis S. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. Pharmaceuticals 2022;15:575. [DOI: 10.3390/ph15050575] [Reference Citation Analysis]
17 Mukherjee K. The 'What, Why, Where and How' of Delivering a Drug. Trends Pharmacol Sci 2020;41:679-80. [PMID: 32946771 DOI: 10.1016/j.tips.2020.08.007] [Reference Citation Analysis]
18 Qiu Y, Clarke M, Wan LTL, Lo JCK, Mason AJ, Lam JKW. Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance. Mol Pharm 2021;18:2218-32. [PMID: 34014665 DOI: 10.1021/acs.molpharmaceut.0c01242] [Reference Citation Analysis]
19 Xu P, Ma Y, Wu H, Wang YL. Placenta-Derived MicroRNAs in the Pathophysiology of Human Pregnancy. Front Cell Dev Biol 2021;9:646326. [PMID: 33777951 DOI: 10.3389/fcell.2021.646326] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ambike S, Cheng CC, Feuerherd M, Velkov S, Baldassi D, Afridi SQ, Porras-Gonzalez D, Wei X, Hagen P, Kneidinger N, Stoleriu MG, Grass V, Burgstaller G, Pichlmair A, Merkel OM, Ko C, Michler T. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res 2021:gkab1248. [PMID: 34928377 DOI: 10.1093/nar/gkab1248] [Reference Citation Analysis]
21 Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med 2021;13:e13243. [PMID: 33821570 DOI: 10.15252/emmm.202013243] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]